within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD03_TrastuzumabEmtansine;

model TrastuzumabEmtansine
  extends Pharmacolibrary.Drugs.ATC.L.L01FD03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FD03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1. It is used primarily for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane. It is an FDA- and EMA-approved therapy for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult female patients with HER2-positive metastatic breast cancer, based on published population PK study.</p><h4>References</h4><ol><li><p>Okamoto, H, et al., &amp; Kuga, H (2020). Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 50(10) 1242–1250. DOI:<a href=\"https://doi.org/10.1080/00498254.2020.1755909\">10.1080/00498254.2020.1755909</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32306807/\">https://pubmed.ncbi.nlm.nih.gov/32306807</a></p></li><li><p>Tamura, K, et al., &amp; Modi, S (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>The Lancet. Oncology</i> 20(6) 816–826. DOI:<a href=\"https://doi.org/10.1016/S1470-2045(19)30097-X\">10.1016/S1470-2045(19)30097-X</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31047803/\">https://pubmed.ncbi.nlm.nih.gov/31047803</a></p></li><li><p>Diéras, V, &amp; Bachelot, T (2014). The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. <i>Targeted oncology</i> 9(2) 111–122. DOI:<a href=\"https://doi.org/10.1007/s11523-013-0287-4\">10.1007/s11523-013-0287-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23852665/\">https://pubmed.ncbi.nlm.nih.gov/23852665</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TrastuzumabEmtansine;
